Mood stabilizers for patients with bipolar disorder: the state of the art

References

• Fatemi SH, Reutiman TJ, Folsom TD. The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder. Biochem. Soc. Trans.37(Pt 5), 1090–1095 (2009).
   PubMedGoogle Scholar
• Angst J. Bipolar disorder a seriously underestimated health burden. Eur. Arch. Psychiatry Clin. Neurosci.254, 59–60 (2004).
   PubMedGoogle Scholar
• Altamura AC, Dell’Osso B, Berlin HA, Buoli M, Bassetti R, Mundo E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur. Arch. Psychiatry Clin. Neurosci.260(5), 385–391 (2010).
   PubMed Web of Science ®Google Scholar
• Angst J, Cui L, Swendsen J et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am. J. Psychiatry167(10), 1194–1201 (2010).
   PubMed Web of Science ®Google Scholar
• Stewart C, El-Mallakh RS. Is bipolar disorder overdiagnosed among patients with substance abuse? Bipolar Disord.9(6), 646–648 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J. Clin. Psychiatry69(11), 1751–1757 (2008).
   PubMedGoogle Scholar
• Kahn JP. Comorbidity and bipolar disorders. Encephale32(Pt 2), S511–S514 (2006).
   Google Scholar
• Dell’Osso B, Buoli M, Bortolussi S, Vecchi V, Camuri G, Altamura AC. Patterns of Axis I comorbidity in relation to age in patients with bipolar disorder: a cross-sectional analysis. J. Affect. Disord. DOI:10.1016/j.jad.2010.10.008 (2010) (Epub ahead of print).
   Google Scholar
• Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry64(5), 543–552 (2007).
   PubMed Web of Science ®Google Scholar
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord.12, 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Fajutrao L, Locklear J, Priaulx J et al. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin. Pract. Epidemiol. Ment. Health5, 3 (2009).
   PubMedGoogle Scholar
• WHO. The global burden of disease: 2004 update. WHO, Geneva, Switzerland (2008).
   Google Scholar
• Ventimiglia J, Kalali AH, McIntyre R. Treatment of bipolar disorder. Psychiatry (Edgmont)6(10), 12–14 (2009).
   PubMedGoogle Scholar
• Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J. Clin Psychopharmacol.16(2 Suppl. 1), S32–S47 (1996).
   Web of Science ®Google Scholar
• Bauer MS, Mitchner L. What is a ‘mood stabilizer’? An evidence-based response. Am. J. Psychiatry161(1), 3–18 (2004).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Richtand N, Tohen M. What makes a drug a primary mood stabilizer? Mol. Psychiatry7(Suppl. 1), S8–S14 (2002).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J. Clin Psychiatry63, 146–151 (2002).
   PubMed Web of Science ®Google Scholar
• Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J. Clin. Psychiatry64(Suppl. 5), 53–61 (2003).
   PubMedGoogle Scholar
• Harris M, Chandran S, Chakraborty N et al. Mood-stabilizers: the archeology of the concept. Bipolar Disord.5, 446–452 (2003).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL. Redefining mood stabilization. J. Affect. Disord.73, 163–169 (2003).
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord.11(3), 225–255 (2009).
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ; on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders The World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J. Biol. Psychiatry5, 120–135 (2004).
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the treatment of acute mania. World J. Biol. Psychiatry10, 85–116 (2009).
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J. Biol. Psychiatry11, 81–109 (2010).
   PubMed Web of Science ®Google Scholar
• Cade JF. Lithium salts in the treatment of psychotic excitement. Med. J. Aust.2(10), 349–352 (1949).
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Greist JH. A computer-based lithium library. Am. J. Psychiatry134(9), 1049 (1977).
   PubMedGoogle Scholar
• Kilts CD. In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium. J. Clin. Psychiatry61(Suppl. 9), 41–46 (2000).
   PubMedGoogle Scholar
• Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin. Pharmacokinet.29(3), 172–191 (1995).
   PubMed Web of Science ®Google Scholar
• Plenge P, Stensgaard A, Jensen HV, Thomsen C, Mellerup ET, Henriksen O. 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol. Psychiatry36(8), 511–516 (1994).
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Nemeroff CB. Lithium. In: Essentials of Clinical Psychopharmacology. American Psychiatric Publishing, VA, USA, 335–336 (2006).
   Google Scholar
• Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell59(3), 411–419 (1989).
   PubMed Web of Science ®Google Scholar
• Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA93(16), 8455–8459 (1996).
   PubMed Web of Science ®Google Scholar
• Williams RS, Harwood AJ. Lithium therapy and signal transduction. Trends Pharmacol. Sci.21(2), 61–64 (2000).
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E, Bouras C et al. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int. J. Neuropsychopharmacol.11(2), 269–287 (2008).
   PubMedGoogle Scholar
• Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res.570(1–2), 333–340 (1992).
   PubMedGoogle Scholar
• Berrettini WH, Nurnberger JI Jr, Narrow W, Simmons-Alling S, Gershon ES. Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann. NY Acad. Sci.487, 197–201 (1986).
   PubMedGoogle Scholar
• El-Mallakh RS. Ion homeostasis and the mechanism of action of lithium. Clin. Neurosci. Res.4(3–4), 227–231 (2004).
   Google Scholar
• Sourial-Bassillious N, Rydelius PA, Aperia A, Aizman O. Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience161(4), 1126–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Natl Acad. Sci. USA95(14), 8363–8368 (1998).
   PubMed Web of Science ®Google Scholar
• Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr. Mol. Pharmacol.2(2), 207–214 (2009).
   PubMedGoogle Scholar
• Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol. Psychiatry DOI: 10.1038/mp.2009.137 (2009) (Epub ahead of print).
   Google Scholar
• Fenves AZ, Emmett M, White MG. Lithium intoxication associated with acute renal failure. South Med. J.77(11), 1472–1474 (1984).
   PubMed Web of Science ®Google Scholar
• Steckler TL. Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hospital. J. Clin. Psychopharmacol.14(5), 336–339 (1994).
   PubMedGoogle Scholar
• Mitchell JE, Mackenzie TB. Cardiac effects of lithium therapy in man: a review. J. Clin. Psychiatry43(2), 47–51 (1982).
   PubMed Web of Science ®Google Scholar
• Hensen J, Haenelt M, Gross P. Lithium induced polyuria and renal vasopressin receptor density. Nephrol. Dial. Transplant.11(4), 622–627 (1996).
   PubMedGoogle Scholar
• Gitlin M. Lithium and the kidney: an updated review. Drug Saf.20, 231–243 (1999).
   PubMedGoogle Scholar
• Le Roy V, Delmas Y, Verdoux H. Chronic renal complications induced by lithium. Encephale35(6), 605–610 (2009).
   PubMedGoogle Scholar
• Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin. Pract. Epidemiol. Ment. Health.12, 2–23 (2006).
   Google Scholar
• Kusalic M, Engelsmann F. Effect of lithium mainteinance therapy on thyroid and parathyroid function. J. Psychiatry Neurosci.24, 227–233 (1999).
   PubMedGoogle Scholar
• Cohen LS, Friedman J, Jefferson JW, Johnson EM, Weiner ML. A re-evaluation of risk of in utero esposure to lithium. JAMA271, 146–150 (1994).
   PubMedGoogle Scholar
• Nora JJ, Nora AH, Toews WH. Ebstein’s anomaly and other congenital heart defects. Lancet2, 594–595 (1974).
   PubMed Web of Science ®Google Scholar
• Menon SJ. Psychotropic medication during pregnancy and lactation. Arch. Gynecol. Obstet.277, 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manic depressive women. Acta Psychiatrica68, 134–139 (1983).
   PubMed Web of Science ®Google Scholar
• Schou M. What happenen later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr. Scand.54, 193–197 (1976).
   PubMed Web of Science ®Google Scholar
• Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can. J. Psychiatry47, 426–436 (2002).
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs23(5), 397–418 (2009).
   PubMed Web of Science ®Google Scholar
• Granneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J. Clin. Psychiatry57(5), 204–206 (1996).
   PubMed Web of Science ®Google Scholar
• Shukla S, Godwin CD, Long LE, Miller MG. Lithium-carbamazepine neurotoxicity and risk factors. Am. J. Psychiatry141(12), 1604–1606 (1984).
   PubMed Web of Science ®Google Scholar
• Karle J, Bjørndal F. Serotonergic syndrome in combination therapy with lithium and fluoxetine. Ugeskr. Laeger.157(9), 1204–1205 (1995).
   PubMedGoogle Scholar
• Sobanski T, Bagli M, Laux G, Rao ML. Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry30(3), 106–107 (1997).
   PubMedGoogle Scholar
• Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry30(6), 272–273 (1997).
   PubMed Web of Science ®Google Scholar
• Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry26(6), 263–264 (1993).
   PubMed Web of Science ®Google Scholar
• Finley PR, O’Brien JG, Coleman RW. Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J. Clin. Psychopharmacol.16(1), 68–71 (1996).
   PubMed Web of Science ®Google Scholar
• Handler J. Lithium and antihypertensive medication: a potentially dangerous interaction. J. Clin. Hypertens.11(12) (2009).
   Google Scholar
• Grunze HC. Anticonvulsants in bipolar disorder. Ment. Health19(2), 127–141 (2010).
   Google Scholar
• Lambert PA, Carraz G, Borselli S et al. Dipropylacetamide in the treatment of manic-depressive psychosis. Encephale1(1), 25–31 (1975).
   PubMedGoogle Scholar
• Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry9(8), 734–755 (2004).
   PubMed Web of Science ®Google Scholar
• Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (Eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics (11th Edition), McGraw-Hill, NY, USA (2006).
   Google Scholar
• Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp. Brain Res.133(3), 334–339 (2000).
   PubMedGoogle Scholar
• Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J. Clin. Psychiatry65(6), 738–739 (2004).
   PubMed Web of Science ®Google Scholar
• Teo R, King J, Dalton E, Ryves J, Williams RS, Harwood AJ. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers. Biochem. Soc. Trans.37(Pt 5), 1110–1114 (2009).
   PubMedGoogle Scholar
• Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin. Drug Metab. Toxicol.5(5), 539–551 (2009).
   PubMed Web of Science ®Google Scholar
• Hermida Ameijeiras J, Tutor Crespo MJ, Tutor Valcarce CJ. Lipase and total amylase and its isoenzymes as markers of pancreatic injury in patients treated with antiepileptic drugs. Farm. Hosp.31, 303–306 (2007).
   PubMedGoogle Scholar
• Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin. Neurosci.52(1), 3–12 (1998).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM. Carbamazepine in manic–depressive illness: a new treatment. Am. J. Psychiatry137(7), 782–790 (1980).
   PubMed Web of Science ®Google Scholar
• Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy20(8 Pt 2), S139–S151 (2000).
   PubMed Web of Science ®Google Scholar
• Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol.12(3), 255–260 (2002).
   PubMed Web of Science ®Google Scholar
• Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf.29(2), 95–118 (2006).
   PubMed Web of Science ®Google Scholar
• Stoner SC, Nelson LA, Lea JW, Marken PA, Sommi RW, Dahmen MM. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy27(1), 68–88 (2007).
   PubMed Web of Science ®Google Scholar
• Bazinet RP. Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? Biochem. Soc. Trans.37(Pt 5), 1104–1109 (2009).
   PubMedGoogle Scholar
• Bowden CL. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord.11(Suppl. 2), 20–33 (2009).
   PubMed Web of Science ®Google Scholar
• Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry77(2), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Misdrahi D, Tournier M, Droulout T et al. Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages. Eur. Psychiatry23(6), 409–412 (2008).
   PubMedGoogle Scholar
• Centorrino F, Albert MJ, Berry JM et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord.5(5), 370–374 (2003).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf.27(3), 173–184 (2004).
   PubMed Web of Science ®Google Scholar
• Gajwani P, Forsthoff A, Muzina D et al. Antiepileptic drugs in mood-disordered patients. Epilepsia46(Suppl. 4), 38–44 (2005).
   PubMedGoogle Scholar
• Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology38(3), 119–130 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen AF, Land GS, Breimer DD et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther.42, 535–541 (1987).
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Pellock JM, Garnett WR et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res.10, 191–200 (1991).
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs63(19), 2029–2050 (2003).
   PubMed Web of Science ®Google Scholar
• Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf.23(1), 35–56 (2000).
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P, Ropert R. Study of 300 case histories of psychotic patients treated with chlorpromazine in closed wards since 1952, Encephale45(4), 528–535 (1956).
   PubMedGoogle Scholar
• Stahl S. Essential Psychopharmacology: Neuroscientific Basis and Practical Application. Cambridge University Press, Cambridge, UK (2000).
   Google Scholar
• Schatzberg AF, Nemeroff CB. Classic antipsychotic medication. In: Essentials of Clinical Psychopharmacology. American Psychiatric Publishing, VA, USA, 211–228 (2006).
   Google Scholar
• Bowden CL, Krishnan AA. Pharmacotherapy for bipolar depression: an economic assessment. Expert Opin. Pharmacoter.5(5), 1101–1107 (2004).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Subramoniam M, Fuller MA. Risperidone in the treatment of bipolar mania. Neuropsychiatr. Dis. Treat.2(2), 127–138 (2006).
   PubMedGoogle Scholar
• McIntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev. Neurother.10(5), 645–649 (2010).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label and dose-ranging study in patients with schizophrenia. Int. Clin. Psychopharmacol.10(4), 239–244 (1995).
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Nemeroff CB. Olanzapine. In: Essentials of Clinical Psychopharmacology. American Psychiatric Publishing, VA, USA, 246 (2006).
   Google Scholar
• Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol.10(1), 7–19 (2007).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G et al. 5HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry155(7), 921–928 (1998).
   PubMed Web of Science ®Google Scholar
• Kassahun K, Mattiuz E, Nyhart E et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos.25(1), 81–93 (1997).
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetik and pharmacodynamic profile. Clin. Pharmacokinet.37(3), 177–193 (1999).
   PubMed Web of Science ®Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharamacol.41(3), 181–186 (1996).
   PubMed Web of Science ®Google Scholar
• Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT. Lack effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy18(6), 1237–1248 (1998).
   PubMedGoogle Scholar
• American Diabetes Association Guidelines. Diabetes Care32(Suppl.1) (2009).
   Google Scholar
• Schatzberg AF, Nemeroff CB. Quetiapine. In: Essentials of Clinical Psychopharmacology. American Psychiatric Publishing, VA, USA, 263 (2006).
   Google Scholar
• Goldstein J. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc.)35, 193–210 (1999).
   PubMed Web of Science ®Google Scholar
• Cascade E, Kalali AH, Mehra S, Meyer JM. Real-world data on atypical antipsychotic medication side effects,. Psychiatry (Edgmont.)7(7), 9–12 (2010).
   PubMedGoogle Scholar
• Cutler A, Datto C, Nordenhem A et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania. Presented at: The 8th Annual International Review of Bipolar Disorders Conference. Copenhagen, Denmark, 14–16 April, 2008.
   Google Scholar
• Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Presented at: The 8th Annual International Review of Bipolar Disorders Conference. Copenhagen, Denmark, 14–16 April, 2008.
   Google Scholar
• Jurdi RK Al, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr. Dis. Treat.6, 29–35 (2010).
   PubMedGoogle Scholar
• Young AH, Mc Elroy, Bauer M et al. A double blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J. Clin. Psychiatry71, 150 (2010).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry71, 163 (2010).
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry55, 5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptors binding. Psychopharmacology (Berl.)124(1–2), 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Heykants J, Huang ML, Mannens G. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry55, 13–17 (1994).
   PubMed Web of Science ®Google Scholar
• Burstein ES, Ma J, Wong S et al. Intrinsic efficacy of antipsychotics at human D2, D3 and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther.315(3), 1278–1287 (2005).
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther.302(1), 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol.441(3), 137–140 (2002).
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28(8), 1400–1411(2003).
   PubMed Web of Science ®Google Scholar
• Currier GW, Citrome LL, Zimbroff DL et al. Intramuscular aripiprazole in the control of agitation. J. Psychiatr. Pract.13(3), 159–169 (2007).
   PubMedGoogle Scholar
• Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorder and substance abuse from their current antipsychotic to aripiprazole. J. Clin. Psychiatry66(6), 756–760 (2005).
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry63(9), 763–771 (2002).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry60(7), 681–690 (2003).
   PubMed Web of Science ®Google Scholar
• De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet.40, 509–522 (2001).
   PubMedGoogle Scholar
• Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology28(2), 402–412 (2003).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Lieberman JA, Weiden PJ et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr.10(11), 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol.23(1), 65–73 (2009).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord.11(2), 45–54 (2009).
   PubMedGoogle Scholar
• Frye MA, Ketter TA, Altshuler Ll et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J. Affect. Disord.48, 91–104 (1998).
   PubMed Web of Science ®Google Scholar
• Calabrese RJ, Kimmel SE, Woyshville MJ et al. Clozapine for tratment-refractory mania. Am. J. Psychiatry153, 759–764 (1996).
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen M, Patel JK. Clozapine in the treatment of refractory psychotic mania. Am. J. Psichiatry157, 982–986 (2000).
   PubMed Web of Science ®Google Scholar
• Macedo-Soares MB, Moreno RA, Rigonatti SP, Lafer B. Efficacy of electroconvulsive therapy in treatment-resistant bipolar disorder: a case series. J. ECT21, 31–34 (2005).
   PubMedGoogle Scholar
• Valentí M, Benabarre A, Bernardo M, García-Amador M, Amann B, Vieta E. Electroconvulsive therapy in the treatment of bipolar depression. Actas Esp. Psiquiatr.35(3), 199–207 (2007).
   PubMed Web of Science ®Google Scholar
• Hallam KT, Smith DI, Berk M. Differences between subjective and objective assessments of the utility of electroconvulsive therapy in patients with bipolar and unipolar depression. J. Affect. Disord.112, 212–218 (2009).
   PubMed Web of Science ®Google Scholar
• Ciapparelli A, Dell’Osso L, Tundo A et al. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J. Clin. Psychiatry62(7), 552–555 (2001).
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E, Sanchez-Moreno J et al. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord.86, 1–10 (2005).
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry57(9), 841–849 (2000).
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd Edition. Oxford University Press, NY, USA (2007).
   Google Scholar
• McIntyre RS, Mancini DA, Parikh S, Kennedy SH. Lithium revisited. Can. J. Psychiatry46(4), 322–327 (2001).
   PubMed Web of Science ®Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry159(7), 1146–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V; RIS-CAN 25 Study Group. Risperidone in acute and continuation treatment of mania. Int. Clin. Psychopharmacol.18(4), 227–235 (2003).
   PubMed Web of Science ®Google Scholar
• Judd LL, Schettler PJ, Akiskal HS et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol.6(2), 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord.9, 531–535 (2007).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv. Rev. Psychiatry18(3), 143–157 (2010).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ. Models of bipolar disease and their clinical implications. Biol. Psychiatry48(6), 428–429 (2000).
   PubMedGoogle Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry59(6), 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr. Clin. North Am.22(3), 667–673 (1999).
   PubMed Web of Science ®Google Scholar
• Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr. Opin. Psychiatry20(1), 23–29 (2007).
   PubMedGoogle Scholar
• Altamura AC, Mundo E, Dell’osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizer in the long-term treatment of bipolar disorder: a 4 years follow-up naturalistic study. J. Affect. Disord.110(1–2), 135–141 (2008).
   PubMed Web of Science ®Google Scholar
• Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol. Psichiatr. Soc.18(3), 179–183 (2009).
   PubMedGoogle Scholar
• Muller-Oelinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology62(1), 43–49 (2010).
   PubMedGoogle Scholar
• Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr.13(9), 790–795 (2008).
   PubMedGoogle Scholar
• Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am. J. Psychiatry167(7), 792–800 (2010).
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr. Scand.121(3), 201–208 (2010).
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J. Clin. Psychopharmacol.30(3), 306–311 (2010).
   PubMed Web of Science ®Google Scholar
• Altamura AC. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they ‘stabilizer’ rather than typical compounds? Int. Clin. Psychopharmacol.11(3), 153–155 (1996).
   PubMed Web of Science ®Google Scholar
• Altamura AC. From the concept of ‘antipsychotic’ to that of ‘multidimensional normostabilizer’: the clinical-therapeutic itinerary of schizophrenia. Giorn. Ital. Psicopat.16, 87–103 (2010).
   Google Scholar
• Post RM, Altshuler LL, Frye MA et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J. Clin. Psychiatry71(9), 1176–1186 (2010).
   PubMedGoogle Scholar
• Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin. Emerg. Drugs15(3), 453–466 (2010).
   PubMed Web of Science ®Google Scholar